(Q35595723)

English

Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study

scientific article published on June 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study (English)

1 reference

Europe PubMed Central

9 August 2017

0 references

multicenter clinical trial

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Rofecoxib Rheumatoid Arthritis Endoscopy Study Group

7

1 reference

Europe PubMed Central

9 August 2017

C. J. Hawkey

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740337

1 January 2024

L. Laine

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740337

1 January 2024

T. Simon

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740337

1 January 2024

H. Quan

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740337

1 January 2024

S. Shingo

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740337

1 January 2024

J. Evans

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740337

1 January 2024

language of work or name

0 references

publication date

1 June 2003

1 reference

Europe PubMed Central

9 August 2017

full work available at URL

https://gut.bmj.com/content/gutjnl/52/6/820.full.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740337

1 January 2024

https://europepmc.org/articles/PMC1773685

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740337

1 January 2024

https://europepmc.org/articles/PMC1773685?pdf=render

Portable Document Format

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740337

1 January 2024

https://syndication.highwire.org/content/doi/10.1136/gut.52.6.820

1 reference

10.1136/GUT.52.6.820

https://api.crossref.org/works/10.1136/GUT.52.6.820

1 January 2024

1 reference

Europe PubMed Central

9 August 2017

52

1 reference

Europe PubMed Central

9 August 2017

6

1 reference

Europe PubMed Central

9 August 2017

820-826

1 reference

Europe PubMed Central

9 August 2017

Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Mucosal erosions in longterm non-steroidal anti-inflammatory drug users: predisposition to ulceration and relation to Helicobacter pylori.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

The pathogenesis and consequence of non steroidal anti-inflammatory drug induced small intestinal inflammation in man.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Gastrointestinal blood loss. Effect of aspirin, fenoprofen, and acetaminophen in rheumatoid arthritis as determined by sequential gastroscopy and radioactive fecal markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

26 September 2018

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

26 September 2018

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protoco

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastrointestinal microbleeding: comparisons between benoxaprofen and other nonsteroidal antiinflammatory agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Towards a better aspirin

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose famotidine for prevention of NSAID ulcers?

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/GUT.52.6.820

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35595723&oldid=2042038578"